Axonics® to Present at the SVB Leerink Global Healthcare Conference

IRVINE, Calif.–(BUSINESS WIRE)–Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable rechargeable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, today announced that Chief Executive Officer Raymond W. Cohen is scheduled for a fireside chat at the 9th Annual SVB Leerink Global Healthcare Conference, Tuesday, February 25, at 3:30pm ET in New York City, and will be available for meetings with institutional investors.

To access the live webcast of the fireside chat, please visit the Events & Presentations page of the Investor Relations section of the Company’s website at ir.axonics.com. A replay of the webcast will be available shortly after the conclusion of the fireside chat and will be archived on the Company’s website for 90 days.

About Axonics Modulation Technologies, Inc.

Axonics, based in Irvine, Calif., has developed and is commercializing novel implantable SNM devices for patients with urinary and bowel dysfunction. These conditions are caused by a miscommunication between the bladder and the brain and significantly impacts quality of life. Overactive bladder affects an estimated 87 million adults in the U.S. and Europe. Another estimated 40 million adults are reported to suffer from fecal incontinence/accidental bowel leakage. SNM therapy has been employed to reduce symptoms and restore pelvic floor function for the past two decades. Reimbursement coverage is well established in the U.S. and Europe. The Axonics System is the first rechargeable SNM system approved for sale in the world, and the first to gain full-body MRI conditional labeling. For more information, visit the Company’s website at www.axonics.com.

Contacts

Axonics’ Contact

Axonics Modulation Technologies, Inc.

Dan Dearen, +1-949-396-6320

President & Chief Financial Officer

ir@axonics.com

Investor & Media Contact
W2Opure

Matt Clawson, +1-949-370-8500

mclawson@w2ogroup.com

Staff

Recent Posts

BioGene Therapeutics to Participate in the 43rd JP Morgan Healthcare Conference

Vancouver, British Columbia--(Newsfile Corp. - January 7, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB:…

1 hour ago

Q2i Secures Patent for PARCA Solution, Revolutionizing Probation and Parole

BOSTON, Jan. 7, 2025 /PRNewswire/ -- Q2i, a leader in digital innovation, is proud to announce…

2 hours ago

McDermott Appoints Krist Werling to Lead Best-In-Class Global Health & Life Sciences Practice

CHICAGO, Jan. 7, 2025 /PRNewswire/ -- International law firm McDermott Will & Emery has appointed Kristian (Krist)…

2 hours ago

DeepScribe receives 98.8* overall performance score in KLAS Research report, with top grades in every category

The KLAS Emerging Company Spotlight includes 15 A+* grades for performance indicators across six categories, based…

2 hours ago

GlobalVetLink Unveils New HorseSync Progressive Web Application to Support Streamlined Workflows for Equine Veterinary Clinics

AMES, Iowa, Jan. 7, 2025 /PRNewswire/ -- Equine veterinarians face the constant challenge of managing…

2 hours ago

Arbital Health Expands Value-Based Care Contracting Capabilities with Acquisition of Senior Actuary Team

Transaction adds 35 new client relationships and broadens capabilities for Arbital Health's technology platform and…

2 hours ago